Patents by Inventor Paul Kwiatkowski
Paul Kwiatkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9701683Abstract: The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Ab1, DCAMKL1, ABL1, Ab1 mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Ab1, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Ax1, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.Type: GrantFiled: August 8, 2016Date of Patent: July 11, 2017Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, Xianming Deng, Nicholas Paul Kwiatkowski
-
Patent number: 9678724Abstract: A system and method for combining text editing and tree encoding for computer programs and related software. Source code for programs and the like are stored using a maintaining a structured tree representation comprising a plurality of nodes, including nodes associated with respective identifiers, operands, operators, variables, and flow control elements in the source code, and nodes associated with formatting aspects of a text-based representation of the source code.Type: GrantFiled: May 29, 2015Date of Patent: June 13, 2017Assignee: Intentional Software CorporationInventors: David Waggoner, Melanie A. Jensenworth, Paul Kwiatkowski, Charles Simonyi
-
Patent number: 9572854Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.Type: GrantFiled: April 6, 2015Date of Patent: February 21, 2017Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: Kenneth C. Anderson, James E. Bradner, Edward Franklin Greenberg, Teru Hideshima, Nicholas Paul Kwiatkowski, Ralph Mazitschek, Stuart L. Schreiber, Jared Shaw, Stephen J. Haggarty
-
Publication number: 20160350084Abstract: A system and method for combining text editing and tree encoding for computer programs and related software. Source code for programs and the like are stored using a maintaining a structured tree representation comprising a plurality of nodes, including nodes associated with respective identifiers, operands, operators, variables, and flow control elements in the source code, and nodes associated with formatting aspects of a text-based representation of the source code.Type: ApplicationFiled: May 29, 2015Publication date: December 1, 2016Applicant: Intentional Software CorporationInventors: David Waggoner, Melanie A. Jensenworth, Paul Kwiatkowski, Charles Simonyi
-
Publication number: 20160347755Abstract: The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Ab1, DCAMKL1, ABL1, Ab1 mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Ab1, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Ax1, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.Type: ApplicationFiled: August 8, 2016Publication date: December 1, 2016Inventors: Nathanael S. Gray, Xianming Deng, Nicholas Paul Kwiatkowski
-
Patent number: 9464091Abstract: The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.Type: GrantFiled: January 13, 2016Date of Patent: October 11, 2016Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, Xianming Deng, Nicholas Paul Kwiatkowski
-
Publication number: 20160122357Abstract: The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.Type: ApplicationFiled: January 13, 2016Publication date: May 5, 2016Inventors: Nathanael S. Gray, Xianming Deng, Nicholas Paul Kwiatkowski
-
Publication number: 20160122323Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.Type: ApplicationFiled: October 18, 2013Publication date: May 5, 2016Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael Gray, Tinghu ZHANG, Nicholas Paul KWIATKOWSKI
-
Publication number: 20160051619Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.Type: ApplicationFiled: April 6, 2015Publication date: February 25, 2016Applicants: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: Kenneth C. Anderson, James E. Bradner, Edward Franklin Greenberg, Teru Hideshima, Nicholas Paul Kwiatkowski, Ralph Mazitschek, Stuart L. Schreiber, Jared Shaw, Stephen J. Haggarty
-
Patent number: 8999289Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.Type: GrantFiled: March 22, 2006Date of Patent: April 7, 2015Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: Kenneth C. Anderson, James E. Bradner, Edward Franklin Greenberg, Teru Hideshima, Nicholas Paul Kwiatkowski, Ralph Mazitschek, Stuart L. Schreiber, Jared Shaw, Stephen J. Haggarty
-
Patent number: 8726237Abstract: Many computer applications involve event driven programming. Unfortunately, it may be burdensome on application developers to develop event handlers in unmanaged code for all relevant events within their computer application. For example, when using COM objects in connection with event handling, the burden of lifetime management may be placed on the application developer. Accordingly, one or more systems and/or techniques for event handling in unmanaged code are disclosed herein. A delegate comprising a first interface and a second interface is provided. The delegate may receive event data from a software platform connected to the first interface and may notify a function of a process connected to the second interface. The delegate self destructs when both the computing platform and the process have released their connections to the respective interfaces, thus mitigating manual coding of lifetime management functionality within the process.Type: GrantFiled: October 28, 2009Date of Patent: May 13, 2014Assignee: Microsoft CorporationInventors: Shawn Van Ness, Paul Kwiatkowski, Nikhil Dang, Martyn Lovell, Benjamin Constable, Gary Henderson
-
Patent number: 8593463Abstract: Many computer applications incorporate and support animation (e.g., interactive user interfaces). Unfortunately, it may be challenging for computer applications and rendering systems to render animation frames at a smooth and consistent rate while conserving system resources. Accordingly, a technique for controlling animation rendering frame rate of an application is disclosed herein. An animation rendering update interval of an animation timer may be adjusted based upon a rendering system state (e.g., a rate of compositing visual layouts from animation frames) of a rendering system and/or an application state (e.g., a rate at which an application renders frames) of an application. Adjusting the animation rendering update interval allows the animation timer to adjust the frequency of performing rendering callback notifications (work requests to an application to render animation frames) to an application based upon rendering system performance and application performance.Type: GrantFiled: October 27, 2009Date of Patent: November 26, 2013Assignee: Microsoft CorporationInventors: Robert Jarrett, Sankhyayan Debnath, Paul Kwiatkowski, Martyn Lovell, Billie Sue Chafins, Paul Gildea, Jay Turney
-
Patent number: 8304451Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel inhibitors of histone deacetylases, tubulin deacetylases, and/or aggresome inhibitors, and pharmaceutically acceptable salts and derivatives thereof. The inventive compounds fall into two classes—“isotubacin” class and “isoisotubacin” class—all of which include a 1,3-dioxane core. The present invention further provides methods for treating disorders regulated by histone deacetylase activity, tubulin deacetylase activity, and/or the aggresome (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, protein degradation disorders, protein deposition disorders, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.Type: GrantFiled: May 2, 2007Date of Patent: November 6, 2012Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: Ralph Mazitschek, Nicholas Paul Kwiatkowski, James Elliot Bradner
-
Publication number: 20120040961Abstract: The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, AbI, DCAMKL1, ABL1, AbI mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS 1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, AxI, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.Type: ApplicationFiled: January 6, 2010Publication date: February 16, 2012Applicant: DANA-FARBER CANCER INSTITUTEInventors: Nathanael S. Gray, Xianming Deng, Nicholas Paul Kwiatkowski
-
Publication number: 20110096076Abstract: Many computer applications incorporate and support animation. Application performance may be enhanced by delegating animation management to an application program interface (animation API) for animation. Accordingly, an animation API for managing animation is disclosed herein. The animation API may be configured to sequentially interpolate values of animation variables defining animation movement of animation objects. The animation API may interpolate the values of the animation variables using animation transitions within animation storyboards. The animation API may be configured to determine durations of animation transitions based upon animation characteristics parameters (e.g., starting position, desiring ending position, starting velocity of an animation variable). Durations and start times of animation transitions may be determined based upon key frames. The animation API may be configured to resolve scheduling conflicts among one or more animation transitions.Type: ApplicationFiled: October 27, 2009Publication date: April 28, 2011Applicant: Microsoft CorporationInventors: Paul Kwiatkowski, Sankhyayan Debnath, Martyn Lovell, Nicolas Brun, Robert Jarrett, Billie Sue Chafins, Paul Gildea, Shawn Van Ness, Jay Turney
-
Publication number: 20090315897Abstract: An animation platform for managing the interpolation of values of one or more animation variables from one or more applications. The animation platform uses animation transitions to interpolate the values of the animation variables. The animation platform uses a continuity parameter to smoothly switch from one animation transition to the next.Type: ApplicationFiled: June 24, 2008Publication date: December 24, 2009Applicant: MICROSOFT CORPORATIONInventors: Paul Kwiatkowski, Sankhyayan Debnath, Jay Edward Turney, Martyn Simon Lovell, Billie Sue Chafins
-
Publication number: 20090315896Abstract: An animation platform for managing the interpolation of values of one or more animation variables from one or more applications. The animation platform uses animation transitions to interpolate the values of the animation variables. When conflicts arise, the animation platform implements application-supplied logic to determine an execution priority of the conflicting animation transitions.Type: ApplicationFiled: June 24, 2008Publication date: December 24, 2009Applicant: MICROSOFT CORPORATIONInventors: Paul Kwiatkowski, Sankhyayan Debnath, Jay Edward Turney, Martyn Simon Lovell, Billie Sue Chafins
-
Publication number: 20090209590Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel inhibitors of histone deacetylases, tubulin deacetylases, and/or aggresome inhibitors, and pharmaceutically acceptable salts and derivatives thereof. The inventive compounds fall into two classes—“isotubacin” class and “isoisotubacin” class—all of which include a 1,3-dioxane core. The present invention further provides methods for treating disorders regulated by histone deacetylase activity, tubulin deacetylase activity, and/or the aggresome (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, protein degradation disorders, protein deposition disorders, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.Type: ApplicationFiled: May 2, 2007Publication date: August 20, 2009Inventors: Ralph Mazitschek, Nicholas Paul Kwiatkowski, James Elliot Bradner
-
Patent number: 6665866Abstract: A compiler architecture uses a question and answer methodology between a reduction engine and nodes of a graph representing the program being compiled to provide for easy expandability of the compiler. By using the question and answer methodology, additional functionality can be added to the compiler by users, whether they be part of the original design team of the compiler or be a subsequent user.Type: GrantFiled: May 28, 1999Date of Patent: December 16, 2003Assignee: Microsoft CorporationInventors: Paul Kwiatkowski, David Richter, William Aitken, Brian Dickens, Charles Simonyi, Muthukrishnan Paramasivam, Steve Eisner, Ioannis Samaragdakis
-
Patent number: 6493869Abstract: A transformation programming system allows code to be inherited. A question and answer methodology is used among question handlers corresponding to nodes of a graph representing the program being transformed. A question handler can inherit code from another question handler by submitting a question requesting the code.Type: GrantFiled: May 28, 1999Date of Patent: December 10, 2002Assignee: Microsoft CorporationInventors: Paul Kwiatkowski, David Richter, M. Paramasivam